Eiger BioPharmaceuticals (EIGR) Announces U.S. Commercial Availability of Zokinvy

Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy™ (lonafarnib) in the United States. Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in November 2020 to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies.

"Eiger sought regulatory approval of Zokinvy to ensure continued access to the only drug proven to reduce the risk of death in patients with Progeria," said Eldon Mayer, Chief Commercial Officer of Eiger. "To fulfill our commitment to patients, we established Eiger OneCare™. This comprehensive program includes personalized support by specialized care managers, reimbursement experts, co-pay assistance for eligible patients and other patient support services designed to assist patients seeking access to Zokinvy."

Most of the identified Zokinvy-eligible patients in the U.S. have received Zokinvy through Eiger's global expanded access program and are now enrolled in Eiger OneCare which will facilitate a smooth transition to Zokinvy commercial supply.

Eiger OneCare will be available Monday through Friday from 9 AM to 5 PM Eastern Time at 1-833-MYEIGER (1-833-693-4437).

For more information, visit www.Zokinvy.com.

For healthcare professionals with questions about Zokinvy, call Eiger's Medical Information department at 833-267-0545.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Red Violet (RDVT) Announces Board Changes
• CEL-SCI Corp (CVM) Appoints Mario Gobbo to Its Board